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Edited by Jesus AvilaAbstract We examined the possibility that I3C, when combined
with a diﬀerentiation stimulus (TPA + CaCl2), would sensitise
SCC cells to a diﬀerentiation stimulus. We report that I3C in-
duces a profound growth inhibition in SCC cells that is dissimilar
to the growth inhibition required to initiate diﬀerentiation. More-
over, we report that I3C, when combined with TPA + CaCl2
treatment, induces a loss of colony forming ability that was dif-
ferentiation and senescence – independent but was due to delayed
cytotoxicity. This study shows that I3C in combination with a
PKC activator + Ca2+ may be a useful therapeutic strategy for
treating oral SCC.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Squamous diﬀerentiation is a complex process in which pro-
liferating keratinocytes residing in the basal layer of stratiﬁed
squamous epithelia undergo an irreversible growth arrest.
This irreversible withdrawal from the cell cycle is followed
by the commitment to diﬀerentiate and the subsequent induc-
tion of diﬀerentiation markers as the cells migrate up through
the suprabasal layers of the epithelial lining. At a molecular
level the process of irreversible growth arrest is characterised
by the reduction in expression of proliferation-associated
genes such as E2F1 and cdc2 [1–3]. In addition, the commit-
ment to diﬀerentiate is characterised by the induction of genes
associated with barrier function such as transglutaminase type
1 (TG-1), involucrin, ﬁlagrin or loricrin [4–6]. This process of
diﬀerentiation is dysregulated in squamous cell carcinomas*Corresponding author. Address: Epithelial Pathobiology Group,
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doi:10.1016/j.febslet.2007.07.009(SCC) such that SCC cells exhibit deregulated proliferation
characterised by the ability to undergo reversible growth ar-
rest but an inability to undergo irreversible growth arrest
[7]. This latter point is important since the ability to undergo
a reversible growth arrest is a property of the proliferation-
competent basal keratinocytes whereas the ability to undergo
an irreversible growth arrest is restricted to those basal cells
committing to a terminal diﬀerentiation programme. Hence,
SCC cells are characterised by dysregulated proliferation,
and an inability to initiate a terminal diﬀerentiation pro-
gramme [8–11].
The transcription factor family, E2F, is a key player in reg-
ulating DNA synthesis [12]. E2F activity is mediated via its
binding to the inhibitory hypophosphorylated form of Rb
[12]. As such E2F is a critical regulator of G1/S phase tra-
verse [12]. Recently, we have shown that E2F is an important
regulator of the initiation of keratinocyte diﬀerentiation [9–
11]. Speciﬁcally, E2F inhibition was shown to be required,
but not suﬃcient, for the initiation of squamous diﬀerentia-
tion in keratinocytes [8,9]. This suggested that inhibition of
E2F activity in diﬀerentiation-incompetent SCC cells may
sensitise them to diﬀerentiation stimuli. In this regard treat-
ment of SCC cells with an E2F dominant/negative + either
phorbol ester treatment or Sp1 overexpression caused the
induction of diﬀerentiation markers in SCC cells [8,9,11].
This provided deﬁnitive proof that SCC cells were diﬀerenti-
ation-competent but were defective in their ability to initiate
diﬀerentiation. These ﬁndings have clinical implications since
it has been proposed that E2F inhibitors could form the basis
for future diﬀerentiation therapies targeted against SCC
[11,12].
Speciﬁc small molecular weight drugs targeting E2F are cur-
rently not available. However, previous reports on the anti-
proliferative action of Indole-3-carbinol (I3C) suggested that
it may be able to act as an indirect-acting E2F inhibitor. This
is based on previous reports that I3C induces a G1/S phase ar-
rest in breast or prostate cancer cell lines characterised by
inhibition of CDK6, Cyclin D and RB and the induction of
the tumour suppressors INK4b (p15), p21 and p27 [13–16].
This suggests that one consequence of I3C action would be
the inhibition of E2F activity. For this reason, we were inter-
ested in exploring the possibility that I3C may act as a sensi-
tiser of diﬀerentiation in head and neck squamous cell
carcinomas.blished by Elsevier B.V. All rights reserved.
Table 1
Indole-3-carbinol causes a dose-dependent inhibition of HEK and
SCC cell growth
Indole-3-carbinol Ec50 (lM) ± S.E.M. (df)
HEK 22.8 ± 5.8 (4)
SCC25 203 ± 75 (4)
KJD 167 ± 45 (4)
Cal 27 278 ± 108 (4)
FaDu 202 ± 56 (4)
Detroit 788 ± 656 (4)
Subconﬂuent cultures of normal human keratinocytes (HEK) or SCC
cell lines were treated with varying doses of indole-3-carbinol for 47 h.
Cells were then incubated with BrdU (10 lM ﬁnal conc.) for a further
1 h and the amount of BrdU incorporation assayed by ELISA. Esti-
mation of the Ec50 values was carried out as described in Section 2.
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2.1. Cell culture and treatments
Human epidermal keratinocytes (HEK) were isolated and cultured
from human neonatal foreskins as described [3]. Foreskins were ob-
tained with approval from the Princess Alexandra Hospital Human
Ethics Committee and consent from the patients parents. The mainte-
nance and culture of the human keratinocyte-derived SCC cell lines,
SCC25, FaDu, Detroit, KJD and Cal-27 has been described [17]. Dif-
ferentiation can be induced in HEKs in response to treatment with 1,3-
tetradecanoyl phorbolacetate (TPA, 50 ng/ml in DMSO) + CaCl2
(1.2 mM) for 48 h, whereas SCC cell lines are resistant to TPA + CaCl2
induced diﬀerentiation.
Colony forming eﬃciency was estimated by trypsinising subconﬂu-
ent cultures of cells that were untreated or had been treated with
TPA + CaCl2 and/or indole-3-carbinol for 48 h (I3C; Sigma, NSW,
Australia; 30 lM for HEK or 600 lM for SCC cells). Varying numbers
of viable cells were then plated out and left for 10 days. Cultures were
then ﬁxed and stained in Coomassie Blue [7] and scanned. Concentra-
tions of I3C used were suﬃcient to cause a substantive growth inhibi-
tion (>50% reduction in BrdU incorporation) in the absence of a
signiﬁcant loss in cell viability. Cell viability was estimated using try-
pan blue exclusion (Sigma, NSW, Australia).
2.2. BrdU assays and cell cycle analysis
Proliferation was estimated by assaying for BrdU incorporation
using a colorimetric assay (Roche Diagnostics, NSW, Australia).
Brieﬂy, 104 cells/well were plated in 96 well plates and 24 h later they
were treated with drug for 48 h ending with a 1-h incubation with
BrdU (10 lM ﬁnal conc.) at 37 C. BrdU incorporation was then esti-
mated as per the manufacturer’s instructions. Cell cycle analysis has
been described previously [18].
2.3. Kinetic analysis
For analysis of the dose-dependent inhibition of BrdU incorporation
in HEKs and SCC cell lines we used a single component dose–response
curve and analysed the data in Prism (GraphPad, USA). From these
analyses we could estimate the concentration of drug required to inhi-
bit proliferation by 50% (Ec50) as well as estimate the standard error of
the estimate of the mean (S.E.M.).
2.4. Quantitative gene expression analysis
Quantitative analysis of gene expression has been described previ-
ously [19,20]. Brieﬂy, following drug treatment, RNA was isolated
using Trizol Reagent (InVitrogen, NSW, Australia) and single strand
cDNA synthesised [19,20]. Primers were designed with the aid of the
PRIMER 3 program (Geneworks, Sydney, NSW, Australia). For
Cdc2 analysis the following primer pair (141 bp product) was used;
Cdc2 forward 5 0CTGGGG TCA GCT CGT TAC TC 3 0, Cdc2 reverse
5 0 AGTGCC CAAAGC TCT GAAAA 3 0. For E2F1 analysis the fol-
lowing primer pair (130 bp product) was used; E2F1 forward 5 0 TGC
AGA GCA GAT GGT TAT GG 3 0, E2F1 reverse 5 0 CTC AGG GCA
CAG GAA AAC AT 3 0. For transglutaminase type 1 (TG-1) analysis
the following primer pair (117 bp product) was used; TG-1 forward 5 0
GTC TTC AAG AAC CCC CTT CC 3 0, TG-1 reverse 5 0 CAC TGT
TTC ATT GCC TCC AA 3 0. For involucrin analysis the following pri-
mer pair (102 bp product) was used; involucrin forward 5 0 GCA AGA
ATG TGA GCA ACA GC 3 0, involucrin reverse 5 0 TGC TCT GGG
TTT TCT GCT TT 3 0. For actin analysis the following primer pairTable 2
I3C can induce a G1/S phase block in some SCC cell lines
HEK SCC25 KJD
– I3C – I3C – I3C
G0/G1 66 76 70 86 54 45
S 24 16 20 6 32 43
G2/M 10 8 10 8 14 12
Proliferating HEKs or SCC cell lines were treated for 48 h with either nothin
then harvested and ﬁxed at 20 C in 70% ethanol and stained with propidiu
experiment was performed on two independent occasions and the data from(100 bp product) was used; actin forward 5 0 GGA CCT GAC TGA
CTA CCT CA 3 0, actin reverse 5 0 AGC TTC TCC TTA ATG TCA
CG 3 0. Reactions were ampliﬁed on a Rotor Gene real time PCR ma-
chine and the data analysed using the Rotor Gene (version 6) software
(Corbett, Brisbane, Qld., Australia).
2.5. Senescence assays
Senescence was estimated by the induction of b-galactosidase activ-
ity [21]. Subconﬂuent cultures of SCC cell lines were incubated with
600 lM I3C in combination with TPA (50 ng/ml) + CaCl2 (1.2 mM)
for 48 h. b-Galactosidase activity was then measured as previously de-
scribed [21].
2.6. Histone deacetylase activity
Total histone deacetylase activity was estimated by the level of his-
tone H3 acetylation that was detectable in total cellular extracts from
SCC25 cells treated with TPA (50 ng/ml) + CaCl2 (1.2 mm) or I3C
(600 lM) alone or combined for 48 h. Brieﬂy, cells were harvested
and protein prepared in sample buﬀer following which 45 lg total cel-
lular protein was electrophoresed, blotted and then incubated with a
mouse monoclonal antibody against acetylated H3 (1:20000; Upstate
Biotechnologies, NSW, #06-599) and visualised by chemiluminescence.
2.7. Autophagy assays
To estimate autophagy we incubated the SCC cell lines with I3C
with or without TPA + CaCl2 for varying lengths of time and then har-
vested protein and determined the levels of expression of the autoph-
agy-speciﬁc marker, LC3/Atg8, using a speciﬁc antibody (1:1000,
Santa Cruz #sc-16756) and chemiluminscent detection.3. Results
3.1. Indole-3-carbinol – induced inhibition of proliferation is
dissimilar to the growth inhibition accompanying the
initiation of diﬀerentiation
The original premise underlying this study was that I3C may
act as an indirect acting inhibitor of E2F that sensitise cells to aCal 27 FaDu Detroit
– I3C – I3C – I3C
72 82 63 60 48 53
22 7 23 23 34 34
6 11 14 17 18 13
g or I3C (30 lM for HEKs and 600 lM for SCC cell lines). Cells were
m iodide for 20 min. Cells were then analysed on a FACScalibur. The
one experiment are shown.
Fig. 1. I3C does not cause hypophosphorylation of Rb. Proliferating
HEKs were treated with 30 lM I3C whilst SCC cell lines were treated
with 600 lM I3C for 48 h. Following this the cells were harvested and
15 lg of protein run on a 7.5% denaturing SDS–PAGE and blotted to
PVDF membrane. Rb phosphorylation status was then determined by
chemiluminescent immunodetection of Rb. Hyperphosphorylated Rb
(Rbpp) runs higher than hypophosphorylated Rb (Rb). Amido black
staining is shown to allow for loading inequality.
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Fig. 2. Proliferation of HEKs and SCC cells treated with I3C or diﬀerentiat
(50 ng/ml) + CaCl2 (1.2 mM ﬁnal conc.) whilst SCC cell lines were treated wit
in the indicated combinations for 47 h following which cells were incubate
incorporation (described in Section 2). BrdU incorporation is presented as a p
presented as means ± S.E.M. of two independent experiments performed in
A.L. Dahler et al. / FEBS Letters 581 (2007) 3839–3847 3841diﬀerentiation stimulus. If true then I3C: (i) should cause a
dose-dependent growth inhibition in the absence of cytotoxic-
ity, (ii) cause a G1/S phase arrest, (iii) cause the accumulation
of hypophosphorylated RB, and (iv) cause a reduction in cdc2
and E2F1 mRNA expression. Treatment of HEKs and oral
SCC cell lines with varying doses of I3C for 48 h resulted in a
dose-dependent inhibition of BrdU incorporation (Table 1).
The Ec50 value for the inhibition of proliferation in HEKs
(22.8 lM) was signiﬁcantly less than that for the oral SCC cell
lines (Ec50 values varying from 167 lM to 788 lM) suggesting
that the mechanism of growth inhibition between cell types
may diﬀer.
To conﬁrm that I3C caused growth inhibition in the absence
of cytotoxicity we treated some of the cells with a growth
inhibitory dose of I3C (30 lM for HEKs and 600 lM for
SCC25, Cal27) for 48 h and then performed a trypan blue
exclusion test. We found no signiﬁcant loss of cell viability in
the cells studied following a 48 h treatment (HEKs = 93 ± 3%
vs 96 ± 1%, Cal 27 = 99 ± 1% vs 94 ± 1%, SCC25 = 98 ± 1% vs0
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ion stimuli. Proliferating HEKs were treated with 30 lM I3C or TPA
h 600 lM I3C or TPA (50 ng/ml) + CaCl2 (1.2 mM ﬁnal conc.) alone or
d with 10 lM BrdU for one more hour and then assayed for BrdU
ercentage of the incorporation observed in the untreated cells. All data
triplicate.
3842 A.L. Dahler et al. / FEBS Letters 581 (2007) 3839–384787 ± 3%, KJD = 82 ± 2.1% vs 86 ± 1.4%, Detroit = 82 ± 3.8 vs
88 ± 3.8%). Next, we examined whether I3C caused a G1/S
phase arrest in the HEKs and SCC cell lines (Table 2). The
I3C-induced growth inhibition in HEKs, SCC25, Cal 27 and
Detroit cells exhibited a modest G1/S phase block whilst the
KJD cells displayed a modest S/G2 block and FaDu’s were
minimally altered (Table 2). In addition, we found no cytotox-
icity as evidenced by a lack of an increase in the sub 2N pop-
ulation of cells following I3C treatment (not shown). These
data were supportive of the notion that I3C may cause an
E2F/Rb-dependent growth inhibition. However, an analysis
of HEKs showed that I3C, at growth inhibitory doses, caused
a modest accumulation of hypophosphorylated Rb in the
HEKs but not in any of the SCC cell lines (Fig. 1). These data
indicate that I3C-dependent growth inhibition is more com-
plex than simply inhibiting Rb:E2F-dependent proliferation.
We had previously shown that the initiation of squamous
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Fig. 3. Proliferation-speciﬁc gene expression in HEKs and SCC cells treated w
30 lM I3C or TPA (50 ng/ml) + CaCl2 (1.2 mM ﬁnal conc.) whilst SCC cell li
ﬁnal conc.) alone or in the indicated combinations for 48 h following which c
proliferation-speciﬁc genes cdc2 (grey bars) and E2F1 (black bars) were t
presented as a percentage of the level of expression estimated in the untre
experiments performed in triplicate and normalised for actin expression.E2F1 mRNA expression [3] and that the inhibition of E2F-
dependent growth in HEKs and SCC cell lines sensitised the
cells to a diﬀerentiation stimulus [10,11]. In normal keratino-
cytes, diﬀerentiation can be stimulated by treatment of HEKs
with TPA + CaCl2. As shown in Fig. 2, TPA + CaCl2 cause an
approximate 60% reduction in BrdU incorporation in HEKs
which is associated with a similar decrease in the expression
of the proliferation genes, cdc2 and E2F1 (Fig. 3). In contrast,
TPA + CaCl2 was unable to cause growth inhibition in the
SCC cell lines (except in the KJD cells). This is not surprising
since SCC cell lines are known to be diﬀerentiation-resistant
[3,7,22]. As stated previously, we chose a concentrations of
I3C that was sub-maximal with respect to growth inhibition
(Fig. 2). This strategy minimised toxicity and maximised the
opportunity for the diﬀerentiation stimuli to elicit a response.
Fig. 2 shows that addition of TPA + CaCl2 to I3C did not en-
hance the growth inhibitory response of SCC cells to I3C treat-
ment alone. Analysis of the expression of proliferation-speciﬁc0
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A.L. Dahler et al. / FEBS Letters 581 (2007) 3839–3847 3843genes in the SCC cell lines in response to I3C alone or in com-
bination with TPA + CaCl2 also indicated that with the excep-
tion of cdc2 in FaDu cells, none of the SCC cell lines
downregulated E2F1 or cdc2 mRNA expression despite being
exposed to a growth inhibitory concentration of drug. This
contrasts markedly to the inhibition of E2F1 and cdc2 mRNA
expression in HEKs in response to a growth-inhibitory and
diﬀerentiative stimuli (Fig. 3). Combined, these data suggest
that the mechanism by which I3C, alone or in combination, in-
duces growth inhibition is dissimilar to the process invoked
during the initiation of squamous diﬀerentiation.
3.2. I3C does not sensitise SCC cell lines to diﬀerentiation
stimuli
Diﬀerentiation of HEKs is an irreversible process in which
diﬀerentiation is initiated by (i) an irreversible growth arrest
followed by (ii) the expression of diﬀerentiation marker genes
[4–6]. Therefore, we tested the ability of I3C alone or in com-
bination with a diﬀerentiation stimulus (TPA + Ca2+) to cause
irreversible growth arrest or induce diﬀerentiation-speciﬁc
genes. Treatment of HEKs with 30 lM I3C resulted in a
reversible growth inhibition whilst treatment of HEKs with
TPA + CaCl2 or I3C in combination with TPA + CaCl2 re-
sulted in an irreversible growth arrest as indicated by a loss
of colony forming ability (Fig. 4). TPA + CaCl2 or I3C alone
failed to reduce colony forming ability in all the SCC cell lines
(with the exception of the Detroit cells) but the combination of
I3C + TPA + CaCl2 produced a reduction in colony forming
ability in all the SCC cell lines except Cal 27s which displayed
only a modest reduction in colony forming ability (Fig. 4).Fig. 4. Colony forming eﬃciency of HEKs and SCC cells treated with
I3C or diﬀerentiation stimuli. Proliferating HEKs were treated with
30 lM I3C or TPA (50 ng/ml) + CaCl2 (1.2 mM ﬁnal conc.) whilst
SCC cell lines were treated with 600 lM I3C or TPA (50 ng/
ml) + CaCl2 (1.2 mM ﬁnal conc.) alone or in the indicated combina-
tions for 48 h following which cells were trypsinised, rinsed and then
plated at varying cell numbers in 6 well plates and allowed to grow for
a further 7–10 days. Plates were then ﬁxed and stained in coomassie
blue. Only wells plated with 100, 300 or 1000 cells are shown. The wells
shown are representative of two independent experiments performed in
duplicate.These data would suggest that a combination of I3C + a diﬀer-
entiation stimuli can induce an irreversible growth arrest in the
majority (4/5) of SCC cell lines, as measured by colony form-
ing ability.
We next made a formal examination of the ability of I3C to
induce squamous diﬀerentiation alone or in combination with
a diﬀerentiation stimulus. Treatment of HEKs with TPA +
CaCl2 resulted in a large induction in the expression of the dif-
ferentiation-speciﬁc genes, TG-1 and involucrin (Fig. 5). How-
ever, we found no consistent evidence that I3C in combination
with a diﬀerentiation stimulus was able to induce squamous
diﬀerentiation markers in the SCC cell lines (Fig. 5). This
was despite the data showing that I3C + TPA + CaCl2 could
reduce colony forming ability in many of the SCC cell lines.
Thus, these data show that I3C is not able to reinstate sensitiv-
ity to a diﬀerentiation stimulus in SCC cells. However, these
data convincingly show that the combination of I3C with
TPA + CaCl2 is able to reduce colony forming ability which
is consistent with either an irreversible growth arrest or a de-
layed cytotoxic reaction. Either way, such an action may have
potential as a therapeutic strategy for treating oral SCCs.3.3. I3C in combination with TPA + CaCl2 causes a delayed
cytotoxic response in SCC cells
Previous studies have shown that some anticancer strategies
such as targetting p53 [23] or siRNAs directed against HPV
gene products in HPV-transformed cells [21] can induce a
senescence-like state as measured by the induction of b-galac-
tosidase activity. We therefore examined whether the loss of
colony forming ability in response to I3C + TPA + CaCl2
was due to the induction of a senescence-like state. KJD, FaDu
and SCC25 cells all expressed a high basal level of b-galactosi-
dase activity that was unaﬀected by TPA + CaCl2 but was re-
duced in cells treated with I3C alone or I3C + TPA + CaCl2
(Fig. 6). In contrast, Detroit and Cal27 cells expressed low,
to negligible, levels of b-galactosidase activity which was unal-
tered by TPA + CaCl2 or I3C alone or in combination (Fig. 6).
These data indicate that the loss of colony forming ability was
not due to the induction of a senescence-like state character-
ised by increased b-galactosidase activity.
Whilst our earlier experiments (trypan blue exclusion and
sub 2N analyses) had excluded cytotoxicity as a cause of I3C
mediated growth inhibition we had not excluded cytotoxicity
as a cause of the loss of colony forming ability. Therefore,
we examined whether the reason for the loss of colony forming
activity was due to a delayed cytotoxic response that was not
evident at 48 h. Fig. 7A shows that treatment of the cell lines
with I3C + TPA + CaCl2 for 48 h was not toxic in all instances
except the FaDu cultures. However, if the cells were treated for
48 h with I3C + TPA + CaCl2 followed by the replacement of
the media with drug-free media for a further 72 h essentially all
the cells died. These data indicated that the loss of colony
forming eﬃciency could be explained by a delayed-onset cyto-
toxic response to I3C + TPA + CaCl2. This is signiﬁcant since
it only occurs in the combination treatment group.
The mechanism underlying the delayed cytotoxic response to
I3C + TPA + CaCl2 is unknown but shared some similarities
to the response of SCC cell lines to the histone deacetylase
(HDAC) inhibitor, SAHA (Erlich, Guminski and Saunders,
unpublished data) and so we tested whether I3C or TPA +
CaCl2 alone or in combination could induce an accumulation
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Fig. 5. Diﬀerentiation-speciﬁc gene expression in HEKs and SCC cells treated with I3C or diﬀerentiation stimuli. Proliferating HEKs were treated
with 30 lM I3C or TPA (50 ng/ml) + CaCl2 (1.2 mM ﬁnal conc.) whilst SCC cell lines were treated with 600 lM I3C or TPA (50 ng/ml) + CaCl2
(1.2 mM ﬁnal conc.) alone or in the indicated combinations for 48 h following which cells were harvested and RNA isolated. mRNA expression levels
for the diﬀerentiation-speciﬁc genes transglutaminase type 1 (TG-1, grey bars) and involucrin (black bars) were then quantitated by quantitative real
time PCR. Expression data are presented as a percentage of the level of expression estimated in the untreated cells. All data presented as
means ± S.E.M. of 2–3 independent experiments performed in triplicate and normalised for actin expression.
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itors. These experiments showed that treatment with
I3C + TPA + CaCl2 did not increase H3 acetylation above
that seen with TPA + CaCl2 or I3C alone at any time studied
(0, 1, 3, 6 and 24 h, data not shown). In contrast, treatment
with the HDACI, TSA for 6 h caused profound H3 acetyla-
tion. These data indicated that I3C does not induce a delayed
cytotoxic response via action as an HDACI.
A delayed cytotoxic response to drugs is frequently associ-
ated with the imposition of a chronic stress on cells. This phe-
nomenon is one of the characteristics of the specialised cell
death response referred to as autophagy [24,25]. Autophagy
is characterised by the induction in expression of LC3/Atg8
[26]. Fig. 7B demonstrates that the autophagy-speciﬁc marker,
LC3/Atg8, is actually reduced in the SCC 25 cell line in re-
sponse I3C or I3C + TPA + CaCl2 treatment for 48 h. In con-
trast, TPA + CaCl2 did not cause such a reduction. These dataindicate that the delayed cytotoxic response of the SCC 25 cells
in response to I3C + TPA + CaCl2 is not accompanied by the
induction of the authophagy-speciﬁc marker, LC3/Atg8.
Moreover, since both I3C treatment of I3C + TPA + CaCl2
treatment reduced LC3/Atg8 expression this would suggest
that the reduced LC3/Atg8 is not responsible for the delayed
cytotoxic response.4. Discussion
In this paper, we report that inhibition of proliferation in
oral SCC cell lines with low dose I3C causes a reversible inhi-
bition of proliferation that diﬀers to that required for the ini-
tiation of diﬀerentiation. Moreover, we show that treatment
of SCC cell lines with a combination of I3C + TPA + CaCl2
results in a loss of colony forming eﬃciency that is not due
Fig. 6. I3C alone, or in combination with a diﬀerentiation stimulus,
does not induce senescence. Proliferating SCC cell lines were treated
with 600 lM I3C or TPA (50 ng/ml) + CaCl2 (1.2 mM) alone or in the
indicated combinations for 48 h following which cells were stained for
b-galactosidase activity. The diﬀuse blue staining is indicative of
b-galactosidase-positive activity. The experiment shown is representa-
tive of two independent experiments.
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Fig. 7. I3C alone, or in combination with a diﬀerentiation stimulus,
causes a delayed cytotoxic response. (A) Proliferating SCC cell lines
were treated with 600 lM I3C + TPA (50 ng/ml) + CaCl2 (1.2 mM
ﬁnal conc.) for 48 h and either assayed for viability or left for a further
72 h in fresh media (120 h) without drug after which viability was
determined by trypan blue exclusion. Data presented as mean-
s ± S.E.M. of triplicate determinations from two independent exper-
iments. (B) Proliferating SCC25 cells were treated with 600 lM I3C or
TPA (50 ng/ml) + CaCl2 (1.2 mM ﬁnal conc.) alone or in the indicated
combinations for 48 h following which cells were harvested and total
cellular protein isolated. Expression level of the autophagy-speciﬁc
marker LC3/Atg8, was then assessed by chemiluminescent immuno-
detection. The amido black stained blot is provided to allow for
loading inequalities.
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senescence or (iii) the induction of autophagy. These data indi-
cate that I3C can induce a profound, yet delayed, cytotoxic re-
sponse when combined with TPA + CaCl2. In addition, our
data indicate that therapeutic strategies employing I3C in com-
bination with other therapeutics such as diﬀerentiating agents
may be of therapeutic beneﬁt in treating oral SCCs.
Indole-3-carbinol is a natural product found in cruciferous
vegetables that has been shown to have a number of signiﬁcant
actions that make it attractive as an anticancer agent or a che-
mopreventive [15]. For example, I3C has been shown to inhibit
proliferation by invoking a G1/S phase arrest characterised by
inhibition of E2F:Rb, CDK6 and Cyclin D activity and the
induction of the tumour suppressors, p21, p27 and p15 [15].
In addition, I3C is able to induce apoptosis in a number of dif-
ferent cancer cell lines by inducing various pro-apoptotic activ-
ities such as Caspase-3 or by inhibiting various anti-apoptotic
activities such as BCl2 [15]. In particular, the apoptotic activity
observed in breast cancer cell lines has been attributed to an
I3C-induced NFjB-dependent inhibition of the anti-apoptotic
BCl2 protein [27].
Despite the large volume of work pertaining to I3C action,
the eﬀects we observed on the SCC cell lines appeared to diﬀer
in a number of signiﬁcant ways to those eﬀects normally attrib-
uted to I3C. For example: (i) I3C did not cause a classical
Rb:E2F-dependent growth inhibition in the SCC cell lines
although it did in the normal keratinocytes, (ii) growth inhibi-
tion caused by I3C was dissimilar to that required for the ini-
tiation of squamous diﬀerentiation, (iii) I3C-induced
cytotoxicity was evident only after 48 hours and was evident
only when combined with TPA + Ca2+, (iv) I3C inhibited theexpression of the senescence marker, b-galactosidase and (v)
I3C inhibited the expression of the autophagy-speciﬁc marker,
LC3/Atg8. These data suggest that the response of SCC cell
lines is complex and may be atypical of the eﬀects noted in
other cancer cell systems. More importantly, the delayed cyto-
toxic response was conserved amongst 4/5 oral SCC cell lines
studied.
Whilst, we did not identify the molecular basis for the ob-
served cytotoxicity it is possible to draw some conclusions
from the present study. For example, we can conclude that
the induction of senescence or diﬀerentiation are not prerequi-
sites for the cytotoxic response and do not precede the cyto-
toxic response. We can also conclude that the delayed
cytotoxic response is unlikely to be via autophagy since we
saw no induction of the autophagy marker, LC3/Atg8 in re-
sponse to the I3C/TPA/ Ca2+ combination. These data would
suggest that the delayed cytotoxicity is attributable to either a
delayed apoptotic response or a delayed necrotic response.
I3C-induced necrosis has not been previously reported whereas
I3C-induced apoptosis appears to be a common response to
3846 A.L. Dahler et al. / FEBS Letters 581 (2007) 3839–3847high dose I3C [15,28,29]. However, the fact that we observed
an I3C delayed cytotoxic response only in the presence of
TPA + Ca2+ would suggest that the mechanism mediating
the cytotoxicity is unique and could include either necrosis
or apoptosis.
A signiﬁcant ﬁnding in this study was the latency in response
to the I3C/TPA/Ca2+ treatment. This latency would suggest
that the direct activation of an apoptotic or necrotic pathway
is unlikely. Several possibilities could explain this latency in ac-
tion. For instance, I3C is known to be labile and metabolised/
transformed [15] to various active derivatives which may be
responsible for the delayed action of the I3C/TPA/Ca2+ com-
bination. Alternatively, the delayed cytotoxicity may be attrib-
utable to a delayed response to TPA. TPA is a potent PKC
activator that is not generally seen as an apoptogen at concen-
trations used to induce diﬀerentiation. However, prolonged
PKC activation leads to PKC downregulation (e.g. see [30])
and thus the eﬀects observed in the present study may be re-
lated to a synergy between I3C and TPA-induced PKC down-
regulation. In this regard, it is noteworthy that the inhibition
of PKC in cancer cells can induce apoptosis [31]. Such a mech-
anism may explain the latency in the cytotoxic response ob-
served in the SCC cell lines in this study. Signiﬁcantly, this
would suggest that therapeutic strategies combining low dose
I3C with low dose PKC inhibitors could prove useful in treat-
ing oral SCCs.
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